Dr. Paul M. Carter, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 42
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of Tennessee, Hsc, College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
TN license 023784 -
Allergy & Immunology (Internal Medicine) Physician
TN license 23784 -
Allergy Physician
TN license 23784
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Allergy Associates, PA (74 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 42
- Services billed
- 76
- Patients’ average age
- 73
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 18 companies reported 91 payments worth $2,290 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $754 |
|---|---|
| Csl Behring | $261 |
| Genzyme Corporation | $257 |
| GlaxoSmithKline, LLC. | $228 |
| Ars Pharmaceuticals Operations, Inc. | $193 |
| Regeneron Healthcare Solutions, Inc. | $162 |
| Genentech USA, Inc. | $85.64 |
| Cycle Pharmaceuticals Inc | $61.92 |
| Food and Beverage | $2,196 |
|---|---|
| Education | $94.62 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Jun 11, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $94.62 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.